ICD-10 code C38.4: Malignant neoplasm of pleura



Key Takeaways

C38.4 is a billable ICD-10-CM diagnosis code for malignant neoplasm of pleura, valid for FY 2026 (effective October 1, 2025).

C38.4 covers both the parietal and visceral pleura, but only for primary, non-mesothelioma malignancy; pleural mesothelioma is coded C45.0 and metastatic (secondary) pleural disease is coded C78.2.

Accurate use of C38.4 requires physician documentation distinguishing primary pleural malignancy from secondary/metastatic disease.

Pabau’s claims management software helps oncology and thoracic practices reduce C38.4 claim errors with structured coding workflows.

ICD-10 Code C38.4: definition and clinical overview

ICD-10 Code C38.4 covers malignant neoplasm of the pleura, and it’s a billable, specific ICD-10-CM code valid for FY 2026. It applies to a primary pleural malignancy that is not mesothelioma; pleural mesothelioma has its own code (C45.0), and cancer that has spread to the pleura from another site is coded C78.2. Knowing what the pleura is and where C38.4 ends and these adjacent codes begin is the key to getting it right.

The pleura is the double-layered membrane surrounding each lung and lining the chest cavity. The outer layer (parietal pleura) adheres to the chest wall; the inner layer (visceral pleura) covers the lung surface. C38.4 captures malignant neoplasms at either layer. It sits within the C38 category (Malignant neoplasm of heart, mediastinum and pleura) and within the broader block C30-C39, classified by the WHO’s ICD-10 browser under malignant neoplasms of respiratory and intrathoracic organs.

For oncology coders and thoracic billing teams, the ICD-10 classification system (browse the full set in our ICD-10 diagnostic code library) provides the structural framework for navigating C38.4 alongside related mediastinal codes.

C38.4 code details: classification and billable status

C38.4 is confirmed billable across all major coding authorities. The CDC/NCHS ICD-10-CM web tool lists it as a valid, specific diagnosis code in every annual update from 2016 through FY 2026. Claims with a date of service on or after October 1, 2015, must use ICD-10-CM codes; C38.4 satisfies that requirement without any additional specificity needed.

Coders should note that C38.4 carries no additional subclassification codes. There is no separate code for parietal versus visceral pleura in ICD-10-CM; both anatomical variants resolve to C38.4. For oncology EMR software workflows, this means the code is terminal: no further specificity is available within ICD-10-CM.

Primary vs. metastatic pleural malignancy: coding implications for ICD-10 Code C38.4

This is where most coding errors occur. The pleura can be the site of three distinct things — primary mesothelioma, another primary pleural tumor, or metastatic spread from elsewhere — and each takes a different code. Only the middle one is C38.4.

Primary pleural malignancy

The best-known primary pleural cancer is malignant pleural mesothelioma, a tumor arising directly from the mesothelial cells lining the pleural cavity. Mesothelioma does not map to C38.4, however: ICD-10-CM assigns pleural mesothelioma to C45.0 (Mesothelioma of pleura), and an Excludes1 relationship keeps C45.0 and C38.4 mutually exclusive. C38.4 is therefore reserved for primary pleural malignancies that are not mesothelioma, such as primary pleural sarcomas. Confirm the histology in the pathology report before choosing between C38.4 and C45.0.

Metastatic pleural involvement

When a malignancy originating elsewhere (lung, breast, gastrointestinal tract) spreads to the pleura, C38.4 does not apply. Metastatic (secondary) pleural malignancy has its own code: C78.2 (Secondary malignant neoplasm of pleura). In these cases coders sequence the primary site code first and assign C78.2 for the secondary pleural involvement. C38.4 is correct only when the pleural tumor is itself primary.

The common error here is reaching for C38.4 whenever the pleura is involved. C38.4 signals a primary pleural tumor; when documentation supports a specific primary site elsewhere with pleural metastasis, the correct pairing is the primary site code plus C78.2 — not C38.4.

Related ICD-10-CM codes in the C38 category

C38.4 sits within a small but precise category. Understanding neighboring codes prevents miscoding when tumors involve adjacent mediastinal structures or overlapping sites. For context on coding another respiratory and intrathoracic condition, our guide on the ICD-10 code for pneumonia due to Streptococcus pneumoniae covers related classification principles.

Two codes outside the C38 category are essential for pleural malignancy work: C45.0 (Mesothelioma of pleura) for mesothelioma histology, and C78.2 (Secondary malignant neoplasm of pleura) for metastatic spread to the pleura. Coders also frequently encounter C34.9 (malignant neoplasm of unspecified part of bronchus or lung) when lung cancer has spread to the pleura; in that scenario the lung primary (C34.9, or a more specific C34.x code reflecting the lobe or side) takes principal diagnosis position, with C78.2 — not C38.4 — for the secondary pleural involvement.

Streamline your oncology coding workflows

Pabau's claims management software helps thoracic and oncology practices structure ICD-10 documentation, reduce C38.4 claim errors, and process reimbursements faster.

Book a demo

Documentation requirements for accurate C38.4 coding

A payable C38.4 claim rests on documentation that does specific work. Generic notes stating “pleural disease” or “possible pleural malignancy” aren’t enough. Coders reviewing records for medical office compliance documentation should confirm these elements are present before assigning C38.4.

• Confirmed malignancy: Pathology or cytology confirming malignant cells. “Suspected” or “rule out” language doesn’t support a C38.4 diagnosis code in outpatient/physician settings.
• Anatomical specificity: The note should identify pleural involvement, whether parietal, visceral, or both. This supports the code and demonstrates medical necessity.
• Primary vs. secondary distinction: The physician should document whether this is a primary pleural tumor or metastatic spread. If metastatic, the primary site must also be documented.
• Histological type (when available): Histology drives code selection — mesothelioma maps to C45.0, while other primary pleural malignancies such as sarcoma map to C38.4. Recording the specific histology prevents miscoding and strengthens audit defensibility.
• Laterality: ICD-10-CM does not further specify left versus right pleura under C38.4, but the physician note should reflect laterality as part of complete clinical documentation.

For practices managing high volumes of oncology claims, clinical documentation workflows that capture these fields at the point of care reduce query rates and downstream denials.

ICD-10 Code C38.4 coding guidelines and sequencing rules

The CMS ICD-10-CM coding guidelines apply across all C38.4 encounter types. The key sequencing rules for pleural malignancy billing follow the standard neoplasm coding hierarchy.

Principal diagnosis selection

When the encounter is focused on treating or diagnosing the pleural malignancy itself (for example, a thoracentesis for diagnostic purposes or initiation of pleural-directed chemotherapy), C38.4 takes principal diagnosis position. No additional sequencing is required unless a primary site elsewhere is the documented driver of the encounter.

Secondary diagnosis sequencing

When a known primary site (such as lung or breast) is the reason for the encounter and pleural spread is an additional finding, the primary site code sequences first, followed by C78.2 (Secondary malignant neoplasm of pleura) for the metastatic pleural involvement — not C38.4, which denotes a primary pleural tumor. This is clinically and financially significant: payers use sequencing to determine which condition drove the episode of care.

ICD-10-CM vs. WHO ICD-10

US coders must use ICD-10-CM, maintained by NCHS, not the WHO international version. The code C38.4 exists in both, but ICD-10-CM includes US-specific coding guidelines, instructional notes, and annual updates not present in the WHO version. Always verify against the CDC/NCHS ICD-10-CM tool rather than the WHO browser for billing purposes.

Practices using digital clinical forms can embed ICD-10-CM version confirmations directly into oncology encounter documentation, reducing the risk of coders inadvertently referencing outdated or international code editions.

ICD-9-CM crosswalk and historical context

Before October 1, 2015, pleural malignancy was coded under ICD-9-CM. The C38.4 equivalent in ICD-9-CM was 163.9 (malignant neoplasm of pleura, unspecified), with 163.0 covering parietal pleura and 163.1 covering visceral pleura. ICD-10-CM consolidated these into the single C38.4 code, removing the parietal/visceral distinction as a separate code decision.

For practices analyzing historical claims data or handling appeals involving older dates of service, the relevant crosswalk maps 163.0, 163.1, and 163.9 to C38.4. The AAPC Codify ICD-10-CM lookup provides verified crosswalk references for the C38 code range.

Thoracic oncology practices tracking coding transitions for audit purposes benefit from patient record management systems that preserve historical ICD-9 entries alongside their ICD-10-CM equivalents within the same clinical record.

Conclusion

Pleural malignancy claims that fail aren’t usually wrong codes. They’re under-documented codes. C38.4 is technically straightforward: billable, specific, and valid through FY 2026. The challenge is ensuring physician documentation supports the code’s use, particularly when distinguishing primary from metastatic disease and sequencing multiple diagnoses correctly.

Pabau’s claims management software gives thoracic and oncology practices the structured documentation workflows needed to capture the clinical detail that supports C38.4 accurately at the point of care. To see how it works in a live oncology billing context, book a demo.

Continue your research

Need a structured framework for oncology documentation? Medical forms at your healthcare practice covers how structured intake workflows reduce claim deficiency rates.

Managing compliance documentation for cancer care billing? HIPAA compliance for medical offices outlines the documentation standards that protect oncology practices during audits.

Looking for software built for complex clinical documentation? Oncology and dermatology practice software from Pabau is designed for practices managing high-specificity diagnosis coding.

Frequently Asked Questions